1. Terumo Aortic recalls all in-date Relay and TREO stent-graft systems over endotoxin risk
Bolton Medical, operating as Terumo Aortic, is recalling all in-date RelayPlus and RelayPro thoracic and TREO abdominal stent-graft systems after an internal review found elevated endotoxin on delivery systems; current testing indicates that about 1% of units may exceed the specification. Since 2023 the company has received 26 complaints of fever, infection, inflammation or sepsis, four with a fatal outcome (a rate of 0.07%); it states that a causal link to this issue is not established but cannot be ruled out. Users are told to stop use and quarantine stock, and implanted patients should be watched for signs of inflammation during the initial hospitalisation and at routine follow-up. For vigilance teams, it is a reminder that low-rate infection and sepsis complaints after implantation can point to a manufacturing quality signal rather than to the procedure alone. BfArM field safety notice, 10 Nov 2026
2. KEYNOTE-867: pembrolizumab with SBRT adds toxicity without benefit in early-stage lung cancer
An interim analysis of the phase 3 KEYNOTE-867 trial, published in the Journal of Clinical Oncology, found that adding pembrolizumab to stereotactic body radiotherapy did not improve event-free survival (HR 0.92) or overall survival (HR 1.33) in 448 patients with unresected stage I or II non-small cell lung cancer. Grade 3 to 5 treatment-related adverse events occurred in 20.4% of patients on pembrolizumab versus 3.7% on placebo, and all five treatment-related deaths were in the pembrolizumab arm. The trial was stopped early on benefit-risk grounds and all study treatment was discontinued. It shows why safety monitoring should be strict when immunotherapy is added to local treatment in early-stage, potentially curable disease, where tolerance for toxicity is low. ASCO Post, 11 Nov 2026
3. Inpatient ibuprofen linked to acute kidney injury, mainly in high-risk patients
In an active-comparator cohort of 78,656 adults admitted to three US hospitals, ibuprofen was associated with higher rates of any acute kidney injury (IRR 1.22), severe acute kidney injury (IRR 1.36) and kidney replacement therapy (IRR 3.29) than oxycodone. The excess risk was concentrated in postoperative (IRR 1.70) and critically ill (IRR 1.65) patients; in low-risk patients (not critically ill, not postoperative, under 60 years, without kidney dysfunction) no increased risk was seen (IRR 0.94), although 87% of them received oxycodone. For safety teams, the study is an example of how an active-comparator design can separate a population at risk from a population that may be treated safely, which is useful for targeted risk minimisation. JAMA Network Open, 10 Nov 2026
4. Tandem corrects more than 80,000 Mobi insulin pumps over false occlusion alarms
Tandem Diabetes Care has issued a correction for more than 80,900 Mobi insulin pumps, mostly distributed in the US, because increased friction in the drive module can trigger false occlusion alarms that suspend insulin delivery until the user responds; repeated false alarms can lead to high blood glucose. The company told MedTech Dive it had received 230 reports of adverse events requiring medical intervention or hospitalisation as of 29 October, with no deaths reported. Users may keep using the pumps but must respond to every occlusion alarm and keep a backup method of insulin delivery. For combination product and device vigilance teams, the case shows how an alarm malfunction can become a drug-exposure problem. MedTech Dive, 11 Nov 2026
This news brief is for information only and is not medical or regulatory advice. Source links open the original publication in a new tab.
Follow Safety Strategy on LinkedIn (opens in a new tab) for updates. All news briefs · News and articles